The impact of candidemia on length of hospital stay, outcome, and overall cost of illness

Clinical Infectious Diseases

Volumn 27, Issue 4, 1998, Pages 781-788

  Rentz, Anne M ^a   Halpern, Michael T ^b   Bowden, Raleigh ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DIPHENHYDRAMINE; FLUCONAZOLE; PETHIDINE; POTASSIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDIASIS; CHILD; COST OF ILLNESS; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPOKALEMIA; MALE; NAUSEA; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; VOMITING;

EID: 2442740075     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514955     Document Type: Article

References (27)

1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275:189-93.
2. Voelker R. New group tracks hospitals' drug-resistant bugs. JAMA 1996; 275:177-8.
3. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571-5.
4. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414-21.
5. Nolla-Salas J, Leon C, Torres-Rodriguez JM, Martin E, Sitges-Serra A. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 1992; 14:952-4.
6. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991; 91(suppl 3B):S86-9.
7. Klein JJ, Watanakinakorn C. Hospital-acquired fungemia: its natural course and clinical significance. Am J Med 1979; 67:51-8.
8. Turner RB, Donowitz LG, Hendley JO. Consequences of candidemia for pediatric patients. AJDC 1985; 139:178-80.
9. Donowitz LG, Hendley JO. Short-course amphotericin B therapy for candidemia in pediatric patients. Pediatrics 1995; 95:888-91.
10. Healthcare Cost and Utilization Project. Nationwide inpatient sample, release 3. Washington, DC: Department of Health and Human Services, U.S. Public Health Service, Agency for Health Care Policy and Research, 1994.
11. Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101:1302-9.
12. Dato VM, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990; 9:309-14.
13. Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14(suppl 1):S120-5.
14. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Arch Intern Med 1995; 155:2429-35.
15. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
16. National Center for Health Statistics. 1990 National Health Interview Survey [database on CDROM]. CD-ROM series 10, no. 4. SETS version 1.22A. Washington, DC: U.S. Government Printing Office, 1995.
17. Simmons WR. Development of the design of the NCHS Hospital Discharge Survey. National Center for Health Statistics; Vital and Health Statistics; Public Health Service. PHS publ. no. 1,000, series 2, no. 39. Washington, DC: U.S. Government Printing Office, September 1970.
18. 1996 Physicians fee & coding guide: a comprehensive fee & coding reference. Augusta, GA: Health Care Consultants of America, 1996.
19. 1997 Drug topics red book. Montvale, NJ: Medical Economics Data Production, 1997.
20. Debusk CH, Daoud R, Thirumoorthi MC, Wilson FM, Khatib R. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994; 26:697-703.
21. Edwards JE Jr. Editorial response, should all patients with candidemia be treated with antifungal agents? Clin Infect Dis 1992; 15:422-3.
22. Hagan ME, Luchi M. Evaluation and treatment of candidemia in the nonneutropenic patient. Compr Ther 1994; 20:459-64.
23. Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25:43-59.
24. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263-72.
25. Van Burik JAH, Bowden RA. Standard antifungal treatment, including role of alternative modalities to administer amphotericin B. In: Meunier F, ed. Clinical infectious diseases. London: Bailliere Tindall, 1995.
26. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16:337-45.
27. Goff DA, Sierawski SJ, Fass RJ. Cost analysis of Candida infection among surgical intensive care unit patients. Clin Drug Invest 1996; 12:176-80.